

#### **VYKAT**

	nformati	on:				_
Name: Member	ID:					$\dashv$
Address						$\dashv$
						4
City, Sta						$\dashv$
Date of I	Sirtn:					
Prescrib	er Inforn	nation:				
Name:						
NPI:						
Phone N	lumber:					
Fax Nun	nber					
Address	:					
City, Sta	te, Zip:					
Request	ed Medic	cation				
Rx Nam	e:					
Rx Strer	ngth					
Rx Quar	ntity:					
Rx Frequ	uency:					
Rx Rout	e of					
Administ	tration:					
Diagnosis and ICD Code:						
prescribed quantities Upon recensive SECTIC request medicar	a medicatican be probeint of the DN A: PI s. Pharritions that	on for your vided. Plea completed ease no nacy pri at are no	fit requires that we review certain requests for coverage with the propertient that requires Prior Authorization before benefit coverage or consecutive the following questions then fax this form to the toll-free red form, prescription benefit coverage will be determined based of the that supporting clinical documentation is required or authorization reviews can be subject to trial with the listed within the criteria. The policies are subject to trial with the criteria and updates to treatment quides.	overage of number lis on the pland d for <b>AL</b> addition o chance	additional ted below. an's rules. LPA nal	
1	Is this requ	uest for initi	al therapy or for a continuation of therapy?			
	[] Initial (If	checked, g	o to 7)			
	[] Continua	ation (If che	cked, go to 2)			

If you have any questions, call: 1-888-258-8250

2	Is the patient currently receiving the requested medication?  [If no, skip to question 7.]	Yes	No
3	Has the patient been receiving medication samples for the requested medication?  [If yes, skip to question 7.]	Yes	No
4	Does the patient have a previously approved prior authorization (PA) on file with the	Yes	No
	current plan?  [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.]  [If no, skip to question 7.]		
5	Has the patient been established on therapy for at least 3 months? [If no, skip to question 7.]	Yes	No
6	Has documentation been submitted to confirm that the patient has had a significant response to therapy, as determined by the provider? ACTION REQUIRED: Submit supporting documentation.  [No further questions.]	Yes	No
7	Is the patient 4 years of age or older with a weight of greater than or equal to 20 kg? [If no, no further questions.]	Yes	No
8	Does the provider attest for females of childbearing potential, use of adequate contraceptive from day 1 until 90 days after last dose of drug?  [If no, no further questions.]	Yes	No
9	Does the provider attest for females who are currently breastfeeding, no breastfeeding will occur until 90 days after last dose of drug?  [If no, no further questions.]	Yes	No
10	Does the provider attest that the patient does not have clinically significant renal or hepatic impairment?  [If no, no further questions.]	Yes	No
11	Has the patient been assessed for hyperglycemia prior to initiating treatment? ACTION REQUIRED: Submit supporting documentation.  [If no, no further questions.]	Yes	No

If you have any questions, call: 1-888-258-8250

12	Does the provider attest that glucose levels will be monitored throughout treatment? [If no, no further questions.]		No
13	Does the provider attest that signs and symptoms of fluid overload will be monitored throughout treatment?  [If no, no further questions.]	Yes	No
14	What is the indication or diagnosis?  [] Hyperphagia associated with Prader-Willi syndrome (PWS) (If checked, go to 15)  [] Other (If checked, no further questions)		
15	Has documentation been provided to confirm the diagnosis of Prader-Willi syndrome (PWS) through genetic testing showing at least one of the following: A) Deletion in the chromosomal 15q11-q13 region, B) Maternal uniparental disomy in chromosome 15, or C) Imprinting defects, translocations, or inversions involving chromosome 15? ACTION REQUIRED: Submit supporting documentation.  [If no, no further questions.]	Yes	No
16	Does the patient have documented symptoms of hyperphagia (For example: food obsession, aggressive food seeking behavior, lack of satiety)? ACTION REQUIRED: Submit supporting documentation.  [If no, no further question.]	Yes	No
17	Is the medication prescribed by or in consultation with a genetic specialist, endocrinologist, or pediatrician with substantial clinical experience in the treatment of Prader-Willi syndrome?  [If no, no further questions.]	Yes	No
18	Does the provider attest that the requested dose is within the Food and Drug Administration (FDA) labeled dose for requested indication and will not exceed a max dose of 525 mg?	Yes	No

	Please document the diagnoses, symptoms, and/or any other information important to this review:
_	



SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

#### FAX COMPLETED FORM TO: 1-833-896-0656

**Disclaimer:** An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

**Confidentiality:** The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any questions, call: 1-888-258-8250

Version 10.2025